Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy

Inclusion Criteria

• •Male or female \> 18 years
• •Histologically confirmed solid tumor.
• •Subjects who have not received chemotherapy and / or radiotherapy in the last 3 months.
• •Subject to initiate a chemotherapy (ie, cycle 1, day 1)
• •The chemotherapy regimen should have an inherent risk of febrile neutropenia of 10-20%.
• •Planning a minimum of 3 cycles chemotherapy.
• •Adequate bone marrow reserve defined by: leukocytes ≥ 3,000 / mm3, platelets ≥ 100.000/mm3; neutrophils ≥ 1,500 / mm3.
• •Adequate hepatic and renal function, defined by: bilirubin \<1.5 times the normal value, ALT and AST \<3 times the normal range (both can be elevated up to 5 times the normal value in patients with known liver metastases); creatinine \<1.5 times upper normal value
• •ECOG ≤ 2.
• •Informed consent